MEL treatment reduced viral brain loads by 3–4 log units and modulated neuroinflammatory markers, notably reducing IL-1β, TNFα, and NF-κB during ZIKV infection, and modulating TNFα, IL-1β, and NF-κB during DENV-4 infection. Here, NFKB1 is linked to Zika virus infectious disease.